Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition Academic Article uri icon

Overview

MeSH Major

  • Graft vs Host Disease
  • Immunity, Innate
  • Lymphocytes
  • Thymus Gland

abstract

  • © 2019 by The American Society of Hematology Patients with multiple myeloma (MM) who achieve minimal residual disease (MRD) negativity after upfront treatment have superior outcomes compared with those who remain MRD1. Recently, associations have been shown between specific commensal microbes and development of plasma cell disorders. Here, we report the association between intestinal microbiota composition and treatment outcome in MM. Microbiota composition of fecal samples collected from 34 MM patients after induction therapy and at the time of flow cytometry–based bone marrow MRD testing was determined by 16S ribosomal RNA sequencing. We observed a higher relative abundance of Eubacterium hallii in the 16 MRD2 patients relative to the 18 MRD1 patients. No association was observed between microbial relative abundance and autologous stem cell transplantation history or MM paraprotein isotype. No differences in microbiota a diversity were observed between MRD2 and MRD1 patients. The potential association of microbiota composition with treatment response in MM patients is an important parameter for additional correlative and clinical investigation.

publication date

  • January 2019

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC6616258

Digital Object Identifier (DOI)

  • 10.1182/bloodadvances.2019032276

PubMed ID

  • 31289031

Additional Document Info

start page

  • 2040

end page

  • 2044

volume

  • 3

number

  • 13